



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयाँ / Units of TATA MEMORIAL CENTRE)
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA
वाराणसी, उत्तर प्रदेश – २२१००५ / VARANASI, UTTAR PRADESH – 221005



Advt. No. HBCH/MPMMCC/PROJECT/2025/27

Date: 18.06.2025

WALK-IN INTERVIEW

Reporting time: 09:00 A.M. to 10:00 A.M.
(Project based vacancies)

Eligible and interested candidates are invited to attend the Walk-In Interview at Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U Campus, Varanasi, Uttar Pradesh – 221005. Candidates must bring Bio-data (Resume), Recent passport size photograph, PAN card, Aadhar card, Educational Certificates, Experience certificates in original and one set of self-attested copies, on the interview date(s).

(1)	Name of Post	Clinical Trial Coordinator
	No. of Vacancy	07 (seven)
	Walk-In Interview Date	Saturday, 21.06.2025
	Monthly Remuneration:	Rs. 25,000/- to Rs. 35,000/-
	Eligibility Criteria	Graduate degree in science with PG Diploma in Clinical Research. Experience of one year in relevant filed is desirable.
	Project Name & A/c No.	(i) IM Project-TRAC (Project A/c 9221) (01-Post) (ii) A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. (Project A/c 9490) (01-Post) (iii) PACIFIC-08: A phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose disease has not progressed following definitive Platinum-based Concurrent Chemo radiation Therapy. (Project A/c No. 160009) (01-Post) (iv) Study Code D9673L00012: A Prospective, Multi-Center, Phase 4, Single Arm Study to assess the safety of Transtuzumab Deruxtecan, an Anti-her2-antibody drug conjugate in Indian patients with unresectable or metastatic her2-based regimen. (Project A/c No. 180003) (01-Post) (v) A randomized, double blind, parallel-group study to Compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU-authorized Keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC). (Project A/c No. 160011) (01-Post) (vi) SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression. (Project A/c No. 160025) (01-Post) (vii) A Phase Ib/III, Open-label, Randomised Study of Capiwasertib plus CKD4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) (Project A/c No. 9256) (01-Post)
(2)	Name of Post	Junior Research Fellow (Non-Medical)
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 23.06.2025
	Monthly Remuneration:	Rs. 40,000/- to Rs. 45,000/-
	Eligibility Criteria	Post-Graduation in life science.
	Project Name & A/c No.	Palliative Triple Oral Metronomic Therapy and Low-Dose Nivolumab with or without Hypo fractionated Radiotherapy: A randomized Phase III Trial (PALLADIUM Trial) (Project A/c No. 160039)
(3)	Name of Post	Clinical Psychologist
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Monday, 23.06.2025
	Monthly Remuneration:	Rs. 25,000/- to Rs. 42,000/-
	Eligibility Criteria	M.A / M. Phill. In Clinical Psychology / General Psychology with minimum 01-year clinical experience. Any Fellowship in Clinical Psychology / Ph.D. is desirable.
	Project Name & A/c No.	Integrated Comprehensive Palliative Care (Project A/c No. 9455)



महामना पंडित मदन मोहन मालवीय कैंसर केंद्र एवं होमी भाभा कैंसर अस्पताल
MAHAMANA PANDIT MADAN MOHAN MALAVIYA CANCER CENTRE
& HOMI BHABHA CANCER HOSPITAL

(टाटा स्मारक केंद्र की इकाईयां / Units of TATA MEMORIAL CENTRE)
परमाणु ऊर्जा विभाग, भारत सरकार / DEPT. OF ATOMIC ENERGY, GOVT. OF INDIA
वाराणसी, उत्तर प्रदेश – २२१००५ / VARANASI, UTTAR PRADESH – 221005



(4)	Name of Post	Research Assistant
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Wednesday, 25.06.2025
	Monthly Remuneration:	Rs. 23,000/-
	Eligibility Criteria	Graduate degree in science.
	Project Name & A/c No.	Academic Fund (Project A/c No. 9299)

(5)	Name of Post	Data Entry Operator
	No. of Vacancy	01 (one)
	Walk-In Interview Date	Wednesday, 25.06.2025
	Monthly Remuneration:	Rs. 21,100/-
	Eligibility Criteria	Graduate degree with a minimum six-month computer course from a recognized institute.
	Project Name & A/c No.	Academic Fund (Project A/c No. 9299)

Note:

1. The tenure will be valid for six months and may be extended further based on satisfactory performance and the institute's requirement.
2. If there are many applicants, an MCQ test will be conducted as a shortlisting criterion, and only eligible candidates will be invited for the interview accordingly.
3. Outstation candidates are advised that accommodation will not be provided.

(Piyush Tripathi)
Administrative Officer III (HRD)